Eli Lilly Q1 Revenue Surges 56% to $19.8B as GLP-1 Drugs Dominate
Eli Lilly posted first-quarter revenue of $19.8 billion, a 56% year-over-year jump that cleared analyst expectations by roughly $2 billion. Adjusted earnings per share came in at $8.55, beating consensus by $1.76. The standout driver was its GLP-1 drug portfolio — Mounjaro alone grew 125% year-over-year, and Zepbound sales nearly doubled — prompting management to raise full-year guidance.
This is one of the most consequential earnings beats in large-cap pharma in years, and it reinforces Eli Lilly's position as the dominant GLP-1 franchise. Investors holding LLY directly benefit, but the ripple effects hit broader healthcare ETFs, competitor obesity drug plays like Novo Nordisk, and any company in the GLP-1 supply chain — from medical devices to food companies facing long-term demand risk.
May 2025: Novo Nordisk Q1 earnings (direct GLP-1 competitor comparison). June 2025: FDA decisions on next-generation obesity drug approvals. July 30, 2025: Eli Lilly Q2 earnings report.
- Eli Lilly to report first quarter earnings before the bell · CNBC
- Eli Lilly Non-GAAP EPS of $8.55 beats by $1.76, revenue of $19.8B beats by $2B · Seeking Alpha
- Lilly's stock rallies as sales of GLP-1 drugs nearly double · MarketWatch
- Eli Lilly in charts: GLP-1 drugs power Q1 as Mounjaro jumps 125% Y/Y · Seeking Alpha
- Eli Lilly posts strong first-quarter earnings as obesity and diabetes drug demand surges · Quartz
- Eli Lilly raises annual forecasts as GLP-1 drugs fuel growth · Investing.com
- Eli Lilly profits more than double as weight-loss drug sales soar · Financial Times
- More than 20,000 people are taking Eli Lilly's weight loss pill Foundayo, CEO says · CNBC
- Earnings call transcript: Eli Lilly beats expectations in Q1 2026 · Investing.com
- Eli Lilly Q1 2026 slides: incretin dominance drives 56% revenue surge · Investing.com
- Lilly projects 2026 revenue of $82B-$85B and non-GAAP EPS of $35.50-$37 as Foundayo launch begins · Seeking Alpha
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block, and the live update timeline (1 update so far).
Want this for every market day?
Aggregated reads 51 sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information — not investment advice.
← Today's brief